SCHEMBL21568161

SCHEMBL21568161

Cc1ccc(NC(=O)Nc2nc3ccc(Cl)cc3s2)cc1C#N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.57
▸ RECQL P46063 1/20 0.57
▸ DYRK1A Q13627 1/20 0.57
▸ FSCN1 Q16658 1/20 0.57
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ LMNA P02545 2/20 0.54
▸ POLB P06746 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ HSD17B10 Q99714 8/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ ATM Q13315 1/20 0.54
▸ CASP3 P42574 4/20 0.53
▸ SENP7 Q9BQF6 4/20 0.53
▸ SENP8 Q96LD8 3/20 0.53
▸ SENP6 Q9GZR1 3/20 0.53
▸ HPGD P15428 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21568083 0.93 KDM4E (0.56) KDM4ERECQLDYRK1AFSCN1MEN1
SCHEMBL21569108 0.91 KDM4E (0.56) KDM4ERECQLDYRK1AFSCN1MEN1
SCHEMBL21568063 0.90 HSD17B10 (0.57) KDM4ERECQLDYRK1AFSCN1MEN1
SCHEMBL21568250 0.89 BLM (0.55) KDM4ERECQLDYRK1AFSCN1MEN1
SCHEMBL21568318 0.89 DYRK1A (0.57) KDM4EDYRK1AMEN1KMT2ALMNA
SCHEMBL21568967 0.88 BLM (0.54) KDM4ERECQLDYRK1AFSCN1MEN1
SCHEMBL21568084 0.88 HSD17B10 (0.60) KDM4ERECQLDYRK1AFSCN1MEN1
SCHEMBL21568179 0.86 KDM4E (0.53) KDM4ERECQLDYRK1AFSCN1MEN1
SCHEMBL21568257 0.84 KDM4E (0.61) KDM4ERECQLDYRK1AFSCN1MEN1
SCHEMBL21568078 0.84 HSD17B10 (0.57) KDM4ERECQLDYRK1AFSCN1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2021-04-22 — — US disclosed
WO-2019217509-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2019-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731985-B2 Compositions and methods for treating cancer VHL, TP53, NUDT1 KDM4E 884/4885RECQL 555/4885DYRK1A 4664/4885
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER VHL, TP53, NUDT1 KDM4E 818/4885RECQL 496/4885DYRK1A 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback